US Patent Issued to Takeda Pharmaceutical on Jan. 20 for "Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack" (Massachusetts Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,880, issued on Jan. 20, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack" was invented by Christina Nurse (Lexington, Mass.) and Xinming Hao (Lexington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks."

The patent was filed on Jan. 12, 2021, under Applicatio...